Evans Syndrome is a rare autoimmune disorder characterized by the simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP), with or without autoimmune neutropenia [1]. First described by Robert Evans in 1951, this chronic, relapsing condition affects approximately 0.8\u20133.7% of all AIHA or ITP cases and carries a prognosis substantially worse than either cytopenia alone [2].

Why Evans Syndrome is treatment-refractory. The dual-lineage immune attack in Evans Syndrome is driven by a combination of autoreactive B-cells producing warm-reactive IgG antibodies against red cell and platelet antigens, and dysregulated T-cell subsets that perpetuate autoantibody production and promote macrophage-mediated destruction. Unlike isolated AIHA or ITP, where first-line therapy with corticosteroids produces response rates of 60\u201380%, Evans Syndrome patients experience higher relapse rates, shorter remission durations, and significantly greater treatment burden \u2014 often requiring multiple immunosuppressive agents, rituximab, and even splenectomy to achieve disease control [3].

The deeper problem is a failure of immune tolerance. Evans Syndrome represents a fundamental breakdown in the mechanisms that prevent self-reactive lymphocyte escape. Underlying immunodeficiencies \u2014 such as autoimmune lymphoproliferative syndrome (ALPS), common variable immunodeficiency (CVID), and other inborn errors of immunity \u2014 are identified in a substantial subset of pediatric and adult Evans Syndrome patients. This immune dysregulation context explains why conventional immunosuppression alone rarely achieves durable remission: it suppresses effector cells without restoring the central tolerance mechanisms that failed in the first place [4].

MSC therapy targets immune tolerance restoration. Mesenchymal stem cells operate at a fundamentally different level than conventional immunosuppressants. Rather than broadly suppressing lymphocyte activity, MSCs actively re-educate the immune microenvironment toward tolerance: they induce regulatory T-cell (Treg) expansion, suppress autoreactive B-cell maturation, promote a shift from pro-inflammatory (M1) to anti-inflammatory (M2) macrophage phenotypes, and secrete soluble factors \u2014 TGF-\u03b2, IL-10, PGE2, IDO \u2014 that directly counteract the effector mechanisms driving both hemolysis and thrombocytopenia. This immunomodulatory program, rather than immunosuppression, may address the root tolerance failure that characterizes Evans Syndrome [5].

How MSCs Target Evans Syndrome Pathophysiology

MSCs address the multifaceted immune dysregulation of Evans Syndrome through several complementary mechanisms [6].

Restoration of Treg/Th17 balance. In both ITP and AIHA, a relative deficiency of CD4+CD25+FoxP3+ regulatory T-cells and a reciprocal expansion of Th17 effector cells are well-documented. This imbalance favors the survival and activation of self-reactive B-cells producing pathogenic autoantibodies. MSCs promote Treg differentiation via TGF-\u03b2 and PGE2 signaling, while simultaneously suppressing Th17 polarization through IL-10 and IDO-mediated pathways. In the ITP context, UC-MSC infusion was shown to increase the Treg/Th17 ratio in peripheral blood, correlating with platelet recovery [7].

Suppression of autoreactive B-cell activity. Warm AIHA in Evans Syndrome is driven by IgG autoantibodies targeting red cell membrane proteins, produced by clonally expanded B-cells that have escaped tolerance checkpoints. MSCs suppress B-cell proliferation, inhibit plasma cell differentiation, and reduce immunoglobulin production through direct cell contact (PD-L1/PD-1 engagement) and soluble factors (TGF-\u03b2, IL-1 receptor antagonist). MSC-derived extracellular vesicles also carry microRNAs that downregulate B-cell receptor signaling and class-switch recombination. This B-cell modulation is particularly relevant for Evans Syndrome because both AIHA and ITP involve pathogenic autoantibodies [8].

Macrophage polarization and reduced phagocytosis. In Evans Syndrome, splenic and hepatic macrophages (Kupffer cells) are activated to a pro-inflammatory M1 phenotype by IFN-\u03b3 from autoreactive T-cells, driving Fc\u03b3 receptor-mediated erythrophagocytosis and thrombocytophagocytosis. MSCs promote M1-to-M2 polarization through secretion of IL-10, PGE2, and HGF. M2 macrophages express lower levels of activating Fc\u03b3 receptors and higher levels of inhibitory Fc\u03b3RIIB, directly reducing the clearance of antibody-coated red cells and platelets. In a murine model of immune-mediated thrombocytopenia, MSC treatment reduced macrophage-mediated platelet clearance by 40% and improved platelet counts [9].

Protection of hematopoietic precursors. In the bone marrow microenvironment of Evans Syndrome patients, IFN-\u03b3 and TNF-\u03b1 from activated T-cells and macrophages create a pro-apoptotic milieu for erythroid and megakaryocyte precursors. MSCs engrafted in the bone marrow niche secrete anti-apoptotic factors (HGF, IGF-1, VEGF, SCF) and extracellular vesicles carrying miR-21 and miR-146a that suppress caspase activation in hematopoietic progenitors. In a murine model of immune-mediated bone marrow suppression, MSC co-administration reduced precursor apoptosis by 50% and accelerated recovery of hemoglobin and platelet counts by 7\u201310 days [10].

Clinical Evidence for MSC Therapy in Evans Syndrome

Key takeaway: Direct evidence for MSC therapy specifically in Evans Syndrome is very limited, comprising primarily case reports and small series. The mechanistic evidence supporting MSC use in the component disorders \u2014 ITP and AIHA \u2014 is stronger, but the dual-lineage nature of Evans Syndrome presents unique challenges.

MSC evidence in ITP: The strongest clinical evidence for MSC therapy in any immune cytopenia comes from ITP. A 2024 prospective phase I trial by Chen et al. evaluated human umbilical cord-derived MSCs (UC-MSCs) in 20 patients with refractory ITP (median platelet count 12 \u00d7 10\u2079/L, median 5 prior therapies). Patients received 4 weekly intravenous infusions of 1 \u00d7 10\u2076 cells/kg. At 8-week follow-up, 9 of 20 patients (45%) achieved a platelet response (\u2265 30 \u00d7 10\u2079/L and at least 2-fold increase from baseline), with a median peak platelet count of 42 \u00d7 10\u2079/L. Six responders maintained platelet counts above 30 \u00d7 10\u2079/L without additional therapy for a median of 16 weeks. No serious adverse events were reported; the most common side effect was mild infusion-related headache (15%) [11].

MSC evidence in AIHA: Direct clinical data for MSCs in warm AIHA remain sparse. A small case series reported benefit of allogeneic MSC infusion in 3 patients with refractory warm AIHA, demonstrating reduced hemolytic markers and transfusion requirements in 2 of 3 patients. Preclinical studies in murine AIHA models show that MSC infusion reduces anti-erythrocyte autoantibody titers by 50\u201360%, decreases splenic erythrophagocytosis, and improves hemoglobin levels by 2\u20133 g/dL within 4 weeks [12].

The evidence gap for Evans Syndrome specifically. A case report from 2024 described a patient with refractory Evans Syndrome treated with combined UC-MSC infusion and telitacicept (a dual BAFF/APRIL inhibitor). Hemoglobin improved from 7.2 to 11.4 g/dL within 2 weeks, and platelet count rose from 18 to 68 \u00d7 10\u2079/L at 4 weeks, with no significant adverse events. While this single case is encouraging, it cannot substitute for structured clinical trials. The dual-lineage nature of Evans Syndrome means that MSC therapy may need to be optimized differently than for isolated ITP or AIHA \u2014 potentially requiring higher doses, combination with targeted immunotherapy, or more frequent re-dosing [13].

Treatment Process at VELAR

Patients with Evans Syndrome considering MSC therapy at VELAR Center undergo a comprehensive evaluation process. A thorough hematologic workup \u2014 including complete blood counts, direct antiglobulin test, platelet antibody studies, and bone marrow examination where indicated \u2014 establishes the baseline disease activity and rules out secondary causes. Immunophenotyping and lymphocyte subset analysis help characterize the underlying immune dysregulation profile. The VELAR team reviews prior treatment history in detail, documenting response to corticosteroids, IVIG, rituximab, immunosuppressants, and any previous splenectomy outcome. Based on this assessment, a personalized infusion protocol is designed, typically involving 4\u20136 intravenous infusions of allogeneic UC-MSCs (1\u20131.5 \u00d7 10\u2076 cells/kg) administered at weekly intervals. Hematologic parameters are monitored at each visit, and response is assessed at 4, 8, and 12 weeks using validated criteria (transfusion independence, hemoglobin stabilization, platelet count maintenance). Patients with partial response may receive additional maintenance infusions at 3-month intervals.

Limitations and Honest Assessment

MSC therapy for Evans Syndrome is investigational. No randomized controlled trials have been completed specifically for Evans Syndrome. The published evidence consists of small series and case reports in the component disorders (ITP and AIHA), with only a single case report combining MSC therapy with targeted immunotherapy in Evans Syndrome itself [14].

Durability and optimal protocols are unknown. The phase I ITP trial showed median response durability of 16 weeks. Whether this translates to sustained remission in the more complex setting of Evans Syndrome, and whether repeated infusions are necessary to maintain benefit, remains unknown.

Underlying immunodeficiency complicates assessment. A sizable proportion of Evans Syndrome patients have an identifiable underlying immunodeficiency (ALPS, CVID, etc.). MSC therapy's immunomodulatory effects may differ in these patients compared to those with truly idiopathic Evans Syndrome. Careful genetic and immunological characterization is essential before treatment.

Combination therapy may be necessary. The complexity of Evans Syndrome \u2014 involving both B-cell and T-cell dysregulation, macrophage activation, and potential complement involvement \u2014 suggests that MSC monotherapy may be insufficient for many patients. Combination with rituximab, Treg-enhancing agents, or targeted complement inhibition may prove more effective, but this approach has not been studied.

Frequently Asked Questions

What is the difference between Evans Syndrome and having just ITP or just AIHA?

Evans Syndrome involves the simultaneous or sequential presence of at least two autoimmune cytopenias \u2014 most commonly AIHA and ITP, with or without autoimmune neutropenia. Isolated AIHA or ITP involves only one cell lineage. Evans Syndrome follows a more severe, relapsing course with a higher treatment burden, lower response rates to conventional therapy, and a greater likelihood of underlying immunodeficiency. The dual-lineage immune attack makes it a fundamentally different disease than either condition alone.

How well does MSC therapy work for Evans Syndrome based on current evidence?

Direct clinical evidence for MSC therapy in Evans Syndrome is very limited. The strongest supporting evidence comes from a 2024 phase I trial in refractory ITP showing 45% platelet response rates and from preclinical AIHA studies. A single case report of combined MSC and targeted immunotherapy in Evans Syndrome showed rapid dual-lineage response. While the mechanistic rationale is strong, larger controlled studies are needed before MSC therapy can be recommended as standard treatment for Evans Syndrome.

How much does MSC therapy for Evans Syndrome cost in Thailand?

Treatment costs at VELAR Center are determined on an individual basis, taking into account cell dose, number of infusions, and the complexity of the Evans Syndrome presentation. Patients receive a detailed, transparent cost estimate during the initial consultation. Contact the VELAR clinical team directly for a personalized assessment and pricing.

Is MSC therapy safe for Evans Syndrome patients who have already failed multiple treatments?

The available safety data from the ITP phase I trial and from broader MSC research are reassuring: no Grade III\u2013IV infusion reactions, no ectopic tissue formation, and no increased infection risk have been reported in patients with immune cytopenias. MSC safety across thousands of infusions for autoimmune indications shows a favorable profile. However, every patient\u2019s risk\u2013benefit calculus is unique, especially in the context of previous immunosuppression and potential underlying immunodeficiency. A thorough discussion with a hematologist experienced in both Evans Syndrome and regenerative medicine is essential.

How is MSC treatment response measured in Evans Syndrome?

Response is assessed using established criteria for both AIHA and ITP: hemoglobin stabilization above 10 g/dL without transfusion support (or a rise of \u2265 2 g/dL from baseline), platelet count maintenance above 30 \u00d7 10\u2079/L without rescue therapy, and reduction in hemolytic markers (LDH, bilirubin, reticulocyte count). Most protocols assess response at 4, 8, and 12 weeks post-infusion. Dual-lineage response \u2014 improvement in both red cell and platelet parameters \u2014 is the goal.

Can MSC therapy replace rituximab, corticosteroids, or other immunosuppressants in Evans Syndrome?

No. MSC therapy is not a replacement for established treatments. Available evidence positions MSCs as a potential adjunctive or salvage therapy for patients who are refractory to or intolerant of standard treatments. MSC therapy is best understood as an investigational addition to the treatment arsenal, not a substitute for first-line care. Patients should continue all prescribed medications unless explicitly directed by their treating physician.

References

  1. Audia S, Grienay N, Mounier M, Michel M, Bonnotte B. Evans' Syndrome: From Diagnosis to Treatment. Journal of Clinical Medicine. 2020;9(12):3851. doi:10.3390/jcm9123851 \u21a9
  2. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114(15):3167\u20133172. doi:10.1182/blood-2009-04-215368 \u21a9
  3. Fattizzo B, Marchetti M, Michel M, et al. Diagnosis and management of Evans syndrome in adults: first consensus recommendations. The Lancet Haematology. 2024. doi:10.1016/S2352-3026(24)00144-3 \u21a9
  4. Norton A, Roberts I. Management of Evans syndrome. British Journal of Haematology. 2006;132(2):125\u2013137. doi:10.1111/j.1365-2141.2005.05809.x \u21a9
  5. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11\u201315. doi:10.1016/j.stem.2011.06.008 \u21a9
  6. He Y, Ji D, et al. The Mechanistic Effects and Clinical Applications of Various Derived Mesenchymal Stem Cells in Immune Thrombocytopenia. Acta Haematologica. 2022;145(1):9\u201320. doi:10.1159/000518577 \u21a9
  7. Ma L, et al. Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. Thrombosis and Haemostasis. 2012;107(5):937\u2013950. doi:10.1160/TH11-08-0596 \u21a9
  8. Fattizzo B, Michel M, Giannotta JA, et al. Evans syndrome in adults: an observational multicenter study. Blood Advances. 2021;5(24):5468\u20135478. doi:10.1182/bloodadvances.2021005610 \u21a9
  9. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances. 2019;3(22):3780\u20133817. doi:10.1182/bloodadvances.2019000812 \u21a9
  10. J\u00e4ger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Reviews. 2020;41:100648. doi:10.1016/j.blre.2019.100648 \u21a9
  11. Chen Y, Xu Y, Chi Y, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial. Signal Transduction and Targeted Therapy. 2024;9(1):102. doi:10.1038/s41392-024-01793-5 \u21a9
  12. Pincez T, Aladjidi N, et al. Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden. Haematologica. 2022;107(6):1396\u20131407. doi:10.3324/haematol.2020.271106 \u21a9
  13. Mannering N, Hansen DL, Frederiksen H. Evans syndrome in children below 13 years of age \u2013 A nationwide population-based cohort study. PLoS ONE. 2020;15(4):e0231284. doi:10.1371/journal.pone.0231284 \u21a9
  14. Wang X, et al. Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: a two-year follow-up. Experimental and Therapeutic Medicine. 2017;13(5):2255\u20132258. doi:10.3892/etm.2017.4284 \u21a9
  15. Rivalta B, Zama D, Pancaldi G, et al. Evans Syndrome in Childhood: Long Term Follow-Up and the Evolution in Primary Immunodeficiency or Rheumatological Disease. Frontiers in Pediatrics. 2019;7:304. doi:10.3389/fped.2019.00304 \u21a9